Adding Dexmedetomidine to Mannitol to Attenuate the Increase of Intracranial Pressure
Status:
RECRUITING
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
Dexmedetomidine is a potent alpha-2 adrenergic receptor agonist. In addition, dexmedetomidine-induced stimulation of the postsynaptic alpha-2 adrenergic receptor on the cerebral blood vessels can cause cerebral vasoconstriction and decrease cerebral blood flow